Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Tissue Eng Regen Med ; 13(12): 2142-2154, 2019 12.
Article in English | MEDLINE | ID: mdl-31373143

ABSTRACT

Blindness due to corneal diseases is a common pathology affecting up to 23 million individuals worldwide. The tissue-engineered anterior human cornea, which is currently being tested in a Phase I/II clinical trial to treat severe corneal trophic ulcers with preliminary good feasibility and safety results. This bioartificial cornea is based on a nanostructured fibrin-agarose biomaterial containing human allogeneic stromal keratocytes and cornea epithelial cells, mimicking the human native anterior cornea in terms of optical, mechanical, and biological behavior. This product is manufactured as a clinical-grade tissue engineering product, fulfilling European requirements and regulations. The clinical translation process included several phases: an initial in vitro and in vivo preclinical research plan, including preclinical advice from the Spanish Medicines Agency followed by additional preclinical development, the adaptation of the biofabrication protocols to a good manufacturing practice manufacturing process, including all quality controls required, and the design of an advanced therapy clinical trial. The experimental development and successful translation of advanced therapy medicinal products for clinical application has to overcome many obstacles, especially when undertaken by academia or SMEs. We expect that our experience and research strategy may help future researchers to efficiently transfer their preclinical results into the clinical settings.


Subject(s)
Biocompatible Materials/chemistry , Corneal Diseases , Epithelium, Corneal , Tissue Engineering , Animals , Corneal Diseases/metabolism , Corneal Diseases/pathology , Corneal Diseases/therapy , Epithelium, Corneal/chemistry , Epithelium, Corneal/metabolism , Epithelium, Corneal/pathology , Epithelium, Corneal/transplantation , Humans , Rabbits
2.
BMJ Open ; 7(9): e016487, 2017 Sep 24.
Article in English | MEDLINE | ID: mdl-28947445

ABSTRACT

INTRODUCTION: There is a need to find alternatives to the use of human donor corneas in transplants because of the limited availability of donor organs, the incidence of graft complications, as well as the inability to successfully perform corneal transplant in patients presenting limbal deficiency, neo-vascularized or thin corneas, etc. We have designed a clinical trial to test a nanostructured fibrin-agarose corneal substitute combining allogeneic cells that mimics the anterior human native cornea in terms of optical, mechanical and biological behaviour. METHODS AND ANALYSIS: This is a phase I-II, randomised, controlled, open-label clinical trial, currently ongoing in ten Spanish hospitals, to evaluate the safety and feasibility, as well as clinical efficacy evidence, of this bioengineered human corneal substitute in adults with severe trophic corneal ulcers refractory to conventional treatment, or with sequelae of previous ulcers. In the initial phase of the trial (n=5), patients were sequentially recruited, with a safety period of 45 days, receiving the bioengineered corneal graft. In the second phase of the trial (currently ongoing), subjects are block randomised (2:1) to receive either the corneal graft (n=10), or amniotic membrane (n=5), as the control treatment. Adverse events, implant status, infection signs and induced neovascularization are evaluated as determinants of safety and feasibility of the bioengineered graft (main outcomes). Study endpoints are measured along a follow-up period of 24 months, including 27 post-implant assessment visits according to a decreasing frequency. Intention to treat, and per protocol, and safety analysis will be performed. ETHICS AND DISSEMINATION: The trial protocol received written approval by the corresponding Ethics Committee and the Spanish Regulatory Authority and is currently recruiting subjects. On completion of the trial, manuscripts with the results of phases I and II of the study will be published in a peer-reviewed journal. TRIAL REGISTRATION: CT.gov identifier: NCT01765244 (Jan2013). EudraCT number: 2010-024290-40 (Dec2012).


Subject(s)
Corneal Diseases/surgery , Corneal Keratocytes/transplantation , Corneal Transplantation/methods , Epithelium, Corneal/transplantation , Tissue Engineering/methods , Adult , Case-Control Studies , Corneal Diseases/pathology , Corneal Keratocytes/cytology , Corneal Transplantation/adverse effects , Epithelium, Corneal/cytology , Female , Humans , Male , Pilot Projects , Treatment Outcome
3.
Eye Contact Lens ; 43(1): e1-e3, 2017 Jan.
Article in English | MEDLINE | ID: mdl-26222098

ABSTRACT

INTRODUCTION: Psoriasis is a common chronic inflammatory skin disease. Ocular manifestations, which occur in 10% to 20% of cases of psoriasis, are usually bilateral and often present during an exacerbation of the psoriasis. Serious corneal involvement is rare but can be devastating. CASE REPORT: Two cases of sterile corneal infiltrates secondary to an exacerbation of psoriasis are presented. Treatment involved the use of 0.02% topical tacrolimus ointment, which resulted in resolution of the symptoms and infiltrates. DISCUSSION AND CONCLUSION: Topical tacrolimus may be considered as an alternative treatment option to corticosteroids in sterile corneal infiltrates.


Subject(s)
Corneal Diseases/drug therapy , Immunosuppressive Agents/therapeutic use , Psoriasis/drug therapy , Tacrolimus/therapeutic use , Administration, Topical , Adult , Corneal Diseases/etiology , Humans , Male , Ointments , Psoriasis/complications
SELECTION OF CITATIONS
SEARCH DETAIL
...